$CRSP
CRISPR Therapeutics AG

2023 Q4 Form 10-Q Financial Statement

#000095017023059476 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $201.2M $0.00
YoY Change 3353333.33% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $36.48M $41.70M
YoY Change 30.32% -36.68%
% of Gross Profit
Research & Development $95.14M $90.70M
YoY Change -8.12% -22.23%
% of Gross Profit
Depreciation & Amortization $4.937M $4.900M
YoY Change -15.55% -2.0%
% of Gross Profit
Operating Expenses $131.6M $132.4M
YoY Change 0.06% -27.44%
Operating Profit -$132.4M
YoY Change -27.4%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $20.00M $20.67M
YoY Change 74.04% 184.57%
Pretax Income $89.58M -$111.7M
YoY Change -174.62% -36.19%
Income Tax $233.0K $400.0K
% Of Pretax Income 0.26%
Net Earnings $89.35M -$112.2M
YoY Change -180.8% -35.75%
Net Earnings / Revenue 44.41%
Basic Earnings Per Share -$1.41
Diluted Earnings Per Share $1.12 -$1.41
COMMON SHARES
Basic Shares Outstanding 79.43M 79.41M
Diluted Shares Outstanding 79.41M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $587.3M $677.0M
YoY Change 58.22% -12.54%
Cash & Equivalents $389.5M $527.8M
Short-Term Investments $197.8M $149.2M
Other Short-Term Assets $14.39M $20.80M
YoY Change -61.85% -43.29%
Inventory
Prepaid Expenses
Receivables $200.0M
Other Receivables $0.00
Total Short-Term Assets $1.908B $1.761B
YoY Change 2.97% -8.91%
LONG-TERM ASSETS
Property, Plant & Equipment $151.9M $156.1M
YoY Change -7.14% -6.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.973M $0.00
YoY Change -96.29% -100.0%
Other Assets $1.975M $2.047M
YoY Change -57.44% -44.41%
Total Long-Term Assets $321.5M $326.2M
YoY Change -17.57% -22.44%
TOTAL ASSETS
Total Short-Term Assets $1.908B $1.761B
Total Long-Term Assets $321.5M $326.2M
Total Assets $2.230B $2.087B
YoY Change -0.6% -11.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.15M $26.15M
YoY Change 39.08% -18.57%
Accrued Expenses $45.34M $66.41M
YoY Change -41.64% -35.5%
Deferred Revenue $4.105M $3.500M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $108.8M $111.2M
YoY Change -10.17% -26.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $958.0K $5.394M
YoY Change -83.95% 1.51%
Total Long-Term Liabilities $958.0K $5.394M
YoY Change -83.95% 1.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $108.8M $111.2M
Total Long-Term Liabilities $958.0K $5.394M
Total Liabilities $346.8M $359.0M
YoY Change -5.66% -10.11%
SHAREHOLDERS EQUITY
Retained Earnings -$999.7M -$1.089B
YoY Change 18.15% 48.07%
Common Stock $2.881B $2.824B
YoY Change 5.24% 4.13%
Preferred Stock
YoY Change
Treasury Stock (at cost) $62.00K $63.00K
YoY Change -1.59% 0.0%
Treasury Stock Shares
Shareholders Equity $1.883B $1.728B
YoY Change
Total Liabilities & Shareholders Equity $2.230B $2.087B
YoY Change -0.6% -11.33%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $89.35M -$112.2M
YoY Change -180.8% -35.75%
Depreciation, Depletion And Amortization $4.937M $4.900M
YoY Change -15.55% -2.0%
Cash From Operating Activities -$96.07M -$39.90M
YoY Change -15.22% -62.08%
INVESTING ACTIVITIES
Capital Expenditures $770.0K $3.100M
YoY Change -87.56% -151.52%
Acquisitions
YoY Change
Other Investing Activities -$80.68M $124.4M
YoY Change -52.35% 33.08%
Cash From Investing Activities -$81.45M $121.3M
YoY Change -53.6% 38.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 38.96M 1.500M
YoY Change 1472.4% -90.07%
NET CHANGE
Cash From Operating Activities -96.07M -39.90M
Cash From Investing Activities -81.45M 121.3M
Cash From Financing Activities 38.96M 1.500M
Net Change In Cash -138.6M 82.90M
YoY Change -51.62% -3237.77%
FREE CASH FLOW
Cash From Operating Activities -$96.07M -$39.90M
Capital Expenditures $770.0K $3.100M
Free Cash Flow -$96.84M -$43.00M
YoY Change -18.97% -56.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37923
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79432446
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
527765000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211885000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1212061000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1603433000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20760000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
37708000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1760586000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1853026000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156122000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163634000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
53130000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
71000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11830000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11635000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
156215000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
156921000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2047000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4640000
CY2023Q3 us-gaap Assets
Assets
2086830000
CY2022Q4 us-gaap Assets
Assets
2243057000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
26152000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27428000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
66405000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77682000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3500000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
176000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
135000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15001000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15842000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
111234000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
121107000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
15823000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
226585000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
228179000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5394000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5969000
CY2023Q3 us-gaap Liabilities
Liabilities
359036000
CY2022Q4 us-gaap Liabilities
Liabilities
367578000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79607064
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78692766
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79426748
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78512450
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2476000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2441000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
180316
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
180316
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2821225000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2734838000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1089047000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-846090000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6797000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15647000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1727794000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2086830000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2243057000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
170000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1192000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90698000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116622000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
292188000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
358090000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18291000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27001000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59683000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
81295000
CY2023Q3 crsp Collaboration Expense
CollaborationExpense
23422000
CY2022Q3 crsp Collaboration Expense
CollaborationExpense
38859000
crsp Collaboration Expense
CollaborationExpense
110250000
crsp Collaboration Expense
CollaborationExpense
103427000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
132411000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
182482000
us-gaap Operating Expenses
OperatingExpenses
462121000
us-gaap Operating Expenses
OperatingExpenses
542812000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-132411000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-182388000
us-gaap Operating Income Loss
OperatingIncomeLoss
-292121000
us-gaap Operating Income Loss
OperatingIncomeLoss
-541620000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20671000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7264000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51819000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11171000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20671000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7264000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51819000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11171000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-111740000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-175124000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-240302000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-530449000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
412000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-575000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2655000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9151000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-112152000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-174549000
us-gaap Net Income Loss
NetIncomeLoss
-242957000
us-gaap Net Income Loss
NetIncomeLoss
-539600000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-100000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-195000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2160000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1820000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8838000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17001000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110041000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-176469000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-234107000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-556796000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.96
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79414098
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78021520
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79063415
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77547771
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79414098
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78021520
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79063415
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77547771
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10010000
CY2022Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25745000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11826000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10346000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24852000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3449000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2090831000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
970000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12782000
CY2022Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
1296000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24543000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1920000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-174549000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1953954000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
5000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4683000
CY2023Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20875000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6259000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53065000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1854896000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16623000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21765000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
480000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77740000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1816028000
CY2023Q3 crsp Stock Issued During Period Value Stock Options Exercised Gross
StockIssuedDuringPeriodValueStockOptionsExercisedGross
647000
CY2023Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
1192000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19968000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2111000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-112152000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1727794000
us-gaap Profit Loss
ProfitLoss
-242957000
us-gaap Profit Loss
ProfitLoss
-539600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14937000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18326000
us-gaap Share Based Compensation
ShareBasedCompensation
62608000
us-gaap Share Based Compensation
ShareBasedCompensation
75142000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
11779000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-12251000
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
2500000
crsp Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-256000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16769000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7062000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11056000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
36261000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-762000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-1729000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
10826000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-595000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2175000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164302000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-382413000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8732000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30997000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
697762000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
923404000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1165094000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
871278000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
456100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83123000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
970000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
23725000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
35144000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23725000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36114000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-195000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
315535000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-429617000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
224060000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
539595000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
510327000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
753000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4919000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
10000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
299000
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
0
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
19252000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
527765000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
494151000
CY2023Q3 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
0
CY2022Q3 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
4053000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11830000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
539595000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
510327000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
149200000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
159300000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
378536000
CY2023Q3 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2023Q3 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
3000
CY2023Q3 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
378534000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1218824000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
301000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7064000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1212061000
CY2023Q3 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1597360000
CY2023Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
302000
CY2023Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
7067000
CY2023Q3 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1590595000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
52592000
CY2022Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2022Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
2000
CY2022Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
52590000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1672164000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
626000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16227000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1656563000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1724756000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
626000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
16229000
CY2022Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1709153000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
6800000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15600000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
783500000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
628400000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
201400000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
619200000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
53100000
CY2023Q3 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
204669000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
197466000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
48547000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33832000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156122000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163634000
CY2023Q3 us-gaap Depreciation
Depreciation
4900000
us-gaap Depreciation
Depreciation
14900000
CY2022Q3 us-gaap Depreciation
Depreciation
5000000
us-gaap Depreciation
Depreciation
18300000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15899000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19241000
CY2023Q3 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16706000
CY2022Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
35010000
CY2023Q3 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
25767000
CY2022Q4 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
11177000
CY2023Q3 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1755000
CY2022Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
983000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3409000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4927000
CY2023Q3 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1506000
CY2022Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3936000
CY2023Q3 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
536000
CY2022Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
1244000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
827000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1164000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
66405000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77682000
CY2022 crsp Accounting Analysis Defer Option Specified Cost
AccountingAnalysisDeferOptionSpecifiedCost
110300000
CY2023Q3 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
27300000
CY2022 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
36100000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q3 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
20989313
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19968000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24543000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62608000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75142000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7230233
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
60.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1383182
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
45.72
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
587085
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
38.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
875589
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
86.14
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7150741
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
56.06
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4830321
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
53.14
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7150741
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
56.06
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
85900000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8734409
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8583680
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8734409
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8583680
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2700000
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.004
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9200000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.017

Files In Submission

Name View Source Status
0000950170-23-059476-index-headers.html Edgar Link pending
0000950170-23-059476-index.html Edgar Link pending
0000950170-23-059476.txt Edgar Link pending
0000950170-23-059476-xbrl.zip Edgar Link pending
crsp-20230930.htm Edgar Link pending
crsp-20230930.xsd Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
crsp-20230930_htm.xml Edgar Link completed
crsp-20230930_lab.xml Edgar Link unprocessable
crsp-20230930_cal.xml Edgar Link unprocessable
crsp-20230930_def.xml Edgar Link unprocessable
crsp-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending